IRIS
DELLA PORTA, MATTEO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.446
AS - Asia 4.486
EU - Europa 1.248
SA - Sud America 669
AF - Africa 222
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 4
Totale 14.090
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.259
SG - Singapore 2.746
CN - Cina 840
BR - Brasile 551
VN - Vietnam 377
FI - Finlandia 282
IE - Irlanda 202
NG - Nigeria 160
IT - Italia 140
HK - Hong Kong 134
DE - Germania 117
FR - Francia 114
CA - Canada 110
GB - Regno Unito 92
IN - India 86
NL - Olanda 73
SE - Svezia 56
JP - Giappone 47
MX - Messico 46
TR - Turchia 43
AR - Argentina 37
IQ - Iraq 34
BD - Bangladesh 32
ES - Italia 29
PL - Polonia 25
ZA - Sudafrica 22
RU - Federazione Russa 21
BE - Belgio 20
CL - Cile 16
PK - Pakistan 16
EC - Ecuador 15
UA - Ucraina 14
VE - Venezuela 14
SA - Arabia Saudita 13
ID - Indonesia 12
PY - Paraguay 12
UZ - Uzbekistan 12
AU - Australia 11
JM - Giamaica 11
JO - Giordania 11
PH - Filippine 11
CO - Colombia 10
IR - Iran 10
KR - Corea 9
GR - Grecia 8
KE - Kenya 8
AE - Emirati Arabi Uniti 7
AT - Austria 7
CH - Svizzera 7
MA - Marocco 7
MY - Malesia 7
PE - Perù 7
CZ - Repubblica Ceca 6
NP - Nepal 6
KZ - Kazakistan 5
LT - Lituania 5
TH - Thailandia 5
TN - Tunisia 5
CR - Costa Rica 4
EG - Egitto 4
IL - Israele 4
NZ - Nuova Zelanda 4
OM - Oman 4
AL - Albania 3
BY - Bielorussia 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
NO - Norvegia 3
PA - Panama 3
RO - Romania 3
UY - Uruguay 3
AO - Angola 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BG - Bulgaria 2
BO - Bolivia 2
CI - Costa d'Avorio 2
EU - Europa 2
GY - Guiana 2
HN - Honduras 2
KG - Kirghizistan 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
MR - Mauritania 2
NI - Nicaragua 2
PT - Portogallo 2
SN - Senegal 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
DZ - Algeria 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
KW - Kuwait 1
Totale 14.076
Salva come PNG Salva come JPEG
Città #
Singapore 1.330
Wilmington 1.027
Chandler 954
Ashburn 471
The Dalles 411
Shanghai 369
San Mateo 356
San Jose 344
Helsinki 282
Ann Arbor 246
Dallas 223
Dublin 201
Boardman 186
Beijing 171
Leawood 165
Benin City 159
Lawrence 159
Princeton 159
New York 134
Woodbridge 121
Hong Kong 120
Ho Chi Minh City 116
Fairfield 101
Hanoi 101
Paris 93
Los Angeles 85
Santa Clara 75
Amsterdam 65
São Paulo 58
Toronto 47
Houston 45
Seattle 40
Tokyo 40
Milan 38
London 37
Buffalo 34
Council Bluffs 26
Orem 26
Charlotte 24
Haiphong 24
Montreal 24
Cambridge 23
Falls Church 23
Norwalk 23
Brussels 20
San Francisco 20
Warsaw 20
San Diego 19
Boston 18
Columbus 18
Kocaeli 18
Brooklyn 17
Redwood City 17
Da Nang 16
Phoenix 16
Monmouth Junction 15
Rio de Janeiro 15
Belo Horizonte 14
Chennai 14
Mexico City 14
Stockholm 14
Chicago 13
Falkenstein 12
Baghdad 11
Nanjing 11
Redmond 11
Tashkent 11
Brasília 10
Curitiba 10
Hillsboro 10
Kingston 10
Mumbai 10
Pune 10
Amman 9
Frankfurt am Main 9
Guangzhou 9
Johannesburg 9
Tappahannock 9
Assago 8
Hangzhou 8
Manchester 8
Naples 8
New Delhi 8
Phủ Lý 8
Atlanta 7
Guarulhos 7
Ankara 6
Athens 6
Biên Hòa 6
Des Moines 6
Istanbul 6
Nairobi 6
Pittsburgh 6
Quito 6
Rome 6
São José do Rio Preto 6
Vancouver 6
Washington 6
Abbiategrasso 5
Bắc Ninh 5
Totale 9.359
Salva come PNG Salva come JPEG
Nome #
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 208
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun. 2015 Jan 9;6:5901. 138
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group 119
Costimulatory molecules and immune checkpoints are differentially expressed on different subsets of dendritic cells 115
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 115
Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. 114
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 114
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 111
Clinical Effects of Driver Somatic mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With allogeneic Hematopoietic Stem-Cell Transplantation 107
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years 107
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes 104
CD34 and CD2 expression in acute promyelocytic leukemia. 101
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML 100
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006 Nov 1;107(9):2206-11. PubMed PMID: 16998940. 100
A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data. 99
Multicenter validation of a simplified method for paroxysmal nocturnal hemoglobinuria screening. 94
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 94
Leukemic transformation of polycythemia vera: a single center study of 23 patients 92
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience. 92
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) 90
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised international prognostic scoring system (IPSS-R) 90
Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. 90
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes 90
Classification and prognostic evaluation of myelodysplastic syndromes 88
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 88
Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications. 87
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). 87
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? 87
Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. 87
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes 87
Prognosis of secondary acute myeloid leukemia 85
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. 85
Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival 85
Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL). 85
Multicentre validation of a reproducible flow cytometric score for the diagnosis of low-risk myelodysplastic syndromes: results of a European LeukemiaNET study. 84
Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors. 83
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 83
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 83
Dendritic cells in acute promyelocytic leukaemia. 82
Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. 82
An unusual clinical presentation of multiple myeloma with involvement of the oro-pharynx. 82
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) 82
Sequence variations in mitochondrial ferritin: distribution in healthy controls and different types of patients. 81
Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes 81
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 81
Importance of classical morphology in the diagnosis of myelodysplastic syndrome. 81
Differentiation of follicular dendritic sarcoma cells into functional myeloid-dendritic cell-like elements. 81
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. 81
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. 80
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. 80
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders 80
27P * Common gene signature expressed by breast and kidney cancers-derived endothelial colony forming cells 80
Clinical and biological implications of driver mutations in myelodysplastic syndromes 79
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet 79
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome 79
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 79
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome 78
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1 78
Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. 78
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 78
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide 78
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 77
Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule. 77
THE IMPACT OF THE DEGREE OF ANEMIA ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME. A BASIS FOR PROGNOSTIC ASSESSMENT AND CLINICAL DECISION MAKING 77
Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance. 77
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 77
Myelodysplastic syndromes and bone marrow microenvironment. 76
Clinical evaluation of extra-hematological comorbidity in myelodysplastic syndromes: "ready-to-wear" versus "made-to-measure" tools. 76
Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. 76
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 76
Alterata espressione dei canali del Ca2+ in cellule progenitrici endoteliali di pazienti affetti da carcinoma cellulare renale, mielofibrosi idiopatica e tumore della mammella 75
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 75
Simian virus 40 and lymphoproliferative disorder. 75
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study 74
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 74
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. 74
Flow cytometric analysis of peripheral blood dendritic cells in patients with severe sepsis. 73
Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells. 73
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell–Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients 73
In vitro Cytotoxic Effect of Trabectedin on JMML AND CMML Cell Populations 72
Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia 72
rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. 72
Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. 72
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 72
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome 72
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia 72
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 72
Prognostic models in myelodysplastic syndromes 71
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. 71
High resolution melting for the identification of mutations in the iron responsive element of the ferritin light chain gene. 70
Second primary malignancies in ruxolitinib-treated myelofibrosis: Real-world evidence from 219 consecutive patients 70
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 70
Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. 70
Novel trial designs for high-risk myelodysplastic syndromes. 69
Treatment of anemia with erythroid stimulating agents in myelodysplastic syndromes. 69
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 69
Myelodysplastic syndromes with bone marrow fibrosis. 69
Flow cytometric detection of accelerated telomere shortening in myelodysplastic syndromes: correlations with aetiological and clinical-biological findings. 69
Morphological features and prognostic implication in a retrospective analysis of 370 patients with myelodysplastic syndrome 69
The Genetics of Myelodysplastic Syndromes: Clinical Relevance 68
Totale 8.443
Salva come PNG Salva come JPEG
Categoria #
all - tutte 97.533
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 97.533
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021162 0 0 0 0 0 0 0 0 0 0 0 162
2021/20221.059 70 12 24 213 23 26 29 132 105 70 323 32
2022/20232.634 374 85 210 325 252 237 5 234 493 210 176 33
2023/20241.356 121 178 278 47 27 115 57 149 20 46 167 151
2024/20252.000 58 51 24 42 22 275 77 238 255 511 234 213
2025/20265.334 880 275 253 433 179 212 1.706 309 289 352 231 215
Totale 14.223